News Article | May 11, 2017
"Since opening its doors a year ago, JLABS @ Toronto has successfully attracted a multitude of promising companies from our province's life sciences community, led by academic hospitals, world-class research institutes, top scientists and a strong health start-up network," said the Honourable Reza Moridi, Minister of Research, Innovation and Science. "They have helped our province continue to build up Ontario's vibrant innovation ecosystem, create good jobs, and strengthen our position in the global knowledge economy while also providing access to incredible resources for our life science entrepreneurs." Johnson & Johnson Innovation seeks to fuel the best science and technology, no matter where it is located, to solve the greatest unmet medical and healthcare needs of our time. In addition to offering emerging life science companies modular lab units, office space, shared core laboratory equipment, business facilities, third-party services and educational events, JLABS links the entrepreneurs of Toronto with the full breadth of Johnson & Johnson Innovation, including opportunities for funding, access to research and development experts from medical technology, consumer healthcare product and the pharmaceutical teams at Janssen Inc. JLABS @ Toronto provides access to scientific, industry and capital funding experts from across the industry, and operates under the JLABS no-strings attached model, which means resident companies can completely retain their intellectual property and there are no first rights of refusal. "Our goal is to support early stage innovators with the resources and network needed to grow, and as evident by the 40 companies that reside within JLABS @ Toronto, we are already accomplishing what we set out to do in just one year of operation," said Melinda Richter, head of JLABS, Johnson & Johnson Innovation. "The no-strings attached model has been very important to our success in attracting so many quality companies, as it allows entrepreneurs the freedom to operate and do what is best for their company. We are hopeful that providing JLABS to the life sciences ecosystem in Toronto will support continued economic growth and development in the region." Since opening last year, JLABS @ Toronto has helped boost the Canadian life sciences ecosystem by hosting more than 5,300 attendees at over 50 events. More than 90 experts from a multitude of industries have spoken at these events in the last year. JLABS @ Toronto resident companies are receiving access to expertise from across the Johnson & Johnson Family of Companies. "Through their world-class incubator, Johnson & Johnson Innovation is providing much needed infrastructure and access to funding sources for early-stage innovators to help drive their ideas forward," said the Honourable Brad Duguid, Minister of Economic Development & Growth. "Ontario welcomes JLABS @ Toronto's innovative and flexible platform, providing a total of 40 companies with access to incredible business resources while allowing researchers to keep the freedom and flexibility they need to be successful." JLABS @ Toronto has facilitated over 150 meetings of startups with visiting funding experts from throughout North America. Through a unique collaboration, JLABS @ Toronto companies will be considered for funding and mentoring from Spectrum 28, a Silicon Valley venture capital firm. The following are the new companies* accepted into JLABS @ Toronto since May 11th, 2016: Following the leadership of the government of Ontario's investment in JLABS @ Toronto, the Johnson & Johnson Alberta Health Innovation Partnership (JAHIP), a collaboration that includes Alberta Economic Development and Trade, Janssen Inc. and the University Hospital Foundation in Edmonton recently opened the doors to JLABS POD @ Alberta, a secure video conference system at the University of Alberta. This is the first- of- its- kind in Canada and will provide an access point to the Johnson & Johnson Innovation family, offering Alberta health researchers and entrepreneurs access to: the Johnson & Johnson Innovation broader network of therapeutic area experts in pharmaceutical, medical devices and consumer and digital health. "Since its launch just one year ago, JLABS @ Toronto has attracted some of the region's brightest and freshest talent," said Chris Halyk, President, Janssen Inc. "The JLABS model in Ontario and now the JLABS POD in Alberta, enables us to boost the Canadian innovation and life sciences ecosystem and provide meaningful resources to help drive exciting new science forward. Janssen is proud to be part of such a strong collaboration of partners that helped make JLABS @ Toronto and JLABS POD @ Alberta a reality." JLABS facilities have incubated more than 207 companies to date and are currently home to over 150 companies advancing biotech, pharmaceutical, medical device, consumer and digital health programs. A total of 35 collaborations have been formed between companies residing at JLABS and the Johnson & Johnson Family of Companies. JLABS @ Toronto is located at MaRS Discovery District and is a collaboration between Johnson & Johnson Innovation LLC, the University of Toronto, MaRS, Janssen Inc., MaRS Innovation and the Government of Ontario. It is also supported by the following hospital partners: Centre for Addiction and Mental Health, the Hospital for Sick Children, Sinai Health System, St. Michael's Hospital, Sunnybrook Health Sciences Centre and University Health Network. All JLABS locations are accepting applications from biotech, pharmaceutical, medical device, consumer and digital health companies. To apply, visit www.jnjinnovation.com/jlabs. About Johnson & Johnson Innovation Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, JLABS, Johnson & Johnson Innovation – JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information please visit: www.jnjinnovation.com. About Johnson & Johnson Innovation, JLABS Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow. At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries. JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property. JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors. JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center (opening in 2018)). For more information about JLABS, please visit www.jlabs.jnjinnovation.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/johnson--johnson-innovation-announces-40-resident-companies-now-at-jlabs--toronto-300455763.html
News Article | May 11, 2017
Hossein Aliabadi, MD, FAAP, Pediatric Urologist at Pediatric Urology Associates, and affiliated with the Children’s Hospitals & Clinics of Minnesota and Park Nicollet Methodist Hospital, has been named a 2017 Top Doctor in Minneapolis, Minnesota. Top Doctor Awards is dedicated to selecting and honoring those healthcare practitioners who have demonstrated clinical excellence while delivering the highest standards of patient care. Dr. Hossein Aliabadi is a very experienced urologist, having been in practice for more than 36 years. His medical career began in India in 1980, when he graduated from the All India Institute of Medical Sciences in New Delhi. After moving to the United States, he completed residencies at Regions Hospital in St. Paul and at the University of Minnesota Medical Center in Minneapolis. Dr. Aliabadi then completed a fellowship at the University of Toronto Hospital for Sick Children in Ontario, Canada. Dr. Aliabadi is certified by the American Board of Urology, has earned the coveted title of Fellow of the American Academy of Pediatrics, and is renowned across Minnesota and beyond as a specialist in pediatric urology. He is a noted expert in prenatally diagnosed fetal anomalies, and in genitourinary tract reconstruction, and has published a number of medical papers in these areas. Dr. Aliabadi is committed to keeping up to date with the latest technological advances in pediatric urology. He does this through his membership of professional organizations including the Society of Laparoendoscopic Surgeons and the American College of Surgeons. His expertise and dedication makes Dr. Hossein Aliabadi a very deserving winner of a 2017 Top Doctor Award. Top Doctor Awards specializes in recognizing and commemorating the achievements of today’s most influential and respected doctors in medicine. Our selection process considers education, research contributions, patient reviews, and other quality measures to identify top doctors.
Back S.A.,Oregon Health And Science University |
Miller S.P.,Hospital for Sick Children |
Miller S.P.,University of Toronto
Annals of Neurology | Year: 2014
With advances in neonatal care, preterm neonates are surviving with an evolving constellation of motor and cognitive disabilities that appear to be related to widespread cellular maturational disturbances that target cerebral gray and white matter. Whereas preterm infants were previously at high risk for destructive brain lesions that resulted in cystic white matter injury and secondary cortical and subcortical gray matter degeneration, contemporary cohorts of preterm survivors commonly display less severe injury that does not appear to involve pronounced glial or neuronal loss. Nevertheless, these milder forms of injury are also associated with reduced cerebral growth. Recent human and experimental studies support that impaired cerebral growth is related to disparate responses in gray and white matter. Myelination disturbances in cerebral white matter are related to aberrant regeneration and repair responses to acute death of premyelinating late oligodendrocyte progenitors (preOLs). In response to preOL death, early oligodendrocyte progenitors rapidly proliferate and differentiate, but the regenerated preOLs fail to normally mature to myelinating cells required for white matter growth. Although immature neurons appear to be more resistant to cell death from hypoxia-ischemia than glia, they display widespread disturbances in maturation of their dendritic arbors, which further contribute to impaired cerebral growth. These complex and disparate responses of neurons and preOLs thus result in large numbers of cells that fail to fully mature during a critical window in development of neural circuitry. These recently recognized forms of cerebral gray and white matter dysmaturation raise new diagnostic challenges and suggest new therapeutic directions centered on reversal of the processes that promote dysmaturation. Ann Neurol 2014;75:469-486 © 2014 American Neurological Association.
Weinstein S.L.,University of Iowa |
Dolan L.A.,University of Iowa |
Wright J.G.,Hospital for Sick Children |
Dobbs M.B.,University of Washington
New England Journal of Medicine | Year: 2013
BACKGROUND: The role of bracing in patients with adolescent idiopathic scoliosis who are at risk for curve progression and eventual surgery is controversial. METHODS: We conducted a multicenter study that included patients with typical indications for bracing due to their age, skeletal immaturity, and degree of scoliosis. Both a randomized cohort and a preference cohort were enrolled. Of 242 patients included in the analysis, 116 were randomly assigned to bracing or observation, and 126 chose between bracing and observation. Patients in the bracing group were instructed to wear the brace at least 18 hours per day. The primary outcomes were curve progression to 50 degrees or more (treatment failure) and skeletal maturity without this degree of curve progression (treatment success). RESULTS: The trial was stopped early owing to the efficacy of bracing. In an analysis that included both the randomized and preference cohorts, the rate of treatment success was 72% after bracing, as compared with 48% after observation (propensity-score-adjusted odds ratio for treatment success, 1.93; 95% confidence interval [CI], 1.08 to 3.46). In the intention-to-treat analysis, the rate of treatment success was 75% among patients randomly assigned to bracing, as compared with 42% among those randomly assigned to observation (odds ratio, 4.11; 95% CI, 1.85 to 9.16). There was a significant positive association between hours of brace wear and rate of treatment success (P<0.001). CONCLUSIONS: Bracing significantly decreased the progression of high-risk curves to the threshold for surgery in patients with adolescent idiopathic scoliosis. The benefit increased with longer hours of brace wear. Copyright © 2013 Massachusetts Medical Society.
Casey J.R.,University of Alberta |
Grinstein S.,Hospital for Sick Children |
Orlowski J.,McGill University
Nature Reviews Molecular Cell Biology | Year: 2010
Protons dictate the charge and structure of macromolecules and are used as energy currency by eukaryotic cells. The unique function of individual organelles therefore depends on the establishment and stringent maintenance of a distinct pH. This, in turn, requires a means to sense the prevailing pH and to respond to deviations from the norm with effective mechanisms to transport, produce or consume proton equivalents. A dynamic, finely tuned balance between proton-extruding and proton-importing processes underlies pH homeostasis not only in the cytosol, but in other cellular compartments as well.
Canton J.,Hospital for Sick Children |
Grinstein S.,Li Ka Shing Knowledge Institute
Trends in Immunology | Year: 2014
In mammals, engagement of Toll-like receptors by microbe-associated molecular patterns enhances the responsiveness of NADPH oxidases. Two recent papers report a similar 'priming' mechanism for the plant oxidase RbohD. Despite lacking structural homology, the functional parallels between plants and animals reveal that a common regulatory logic arose by convergent evolution. © 2014 Elsevier Ltd.
Cemma M.,Hospital for Sick Children
Current biology : CB | Year: 2012
Autophagy is a conserved cellular degradative pathway that is now established to be a vital part of the host immune response to microbial infection. Autophagy can directly eliminate intracellular pathogens by mediating their delivery to lysosomes. Canonical autophagy is characterized by the formation of a double-membrane autophagosome and the involvement of over 35 autophagy-related proteins (Atgs), including a commonly used autophagosome marker in mammalian cells, LC3. Recent studies have shown that a subset of autophagy components can lead to LC3 conjugation onto phagosomes. This process of LC3-associated phagocytosis (LAP) results in the degradation of the cargo by promoting phagosome fusion with lysosomes. Other components of the autophagy machinery also play roles in immunity that are distinct from the canonical autophagy and LAP pathways. This minireview highlights the complicated relationship between autophagy components and intracellular bacteria, including bacterial targeting mechanisms and the interaction between autophagy and effectors/toxins secreted by bacteria. Copyright © 2012 Elsevier Ltd. All rights reserved.
Lingwood C.A.,Hospital for Sick Children
Cold Spring Harbor perspectives in biology | Year: 2011
The combination of carbohydrate and lipid generates unusual molecules in which the two distinctive halves of the glycoconjugate influence the function of each other. Membrane glycolipids can act as primary receptors for carbohydrate binding proteins to mediate transmembrane signaling despite restriction to the outer bilayer leaflet. The extensive heterogeneity of the lipid moiety plays a significant, but still largely unknown, role in glycosphingolipid function. Potential interplay between glycolipids and their fatty acid isoforms, together with their preferential interaction with cholesterol, generates a complex mechanism for the regulation of their function in cellular physiology.
Flannagan R.S.,Hospital for Sick Children |
Jaumouille V.,Hospital for Sick Children |
Grinstein S.,Hospital for Sick Children
Annual Review of Pathology: Mechanisms of Disease | Year: 2012
Engulfment and destruction of invading microorganisms by phagocytosis are critical components of the innate immune response. In addition, phagocytosis is also required for the clearance of apoptotic bodies, an essential aspect of tissue homeostasis and remodeling. Here, we summarize the current knowledge of the cellular and molecular basis of phagosome formation and maturation. We discuss the manner in which phagocytosis is subverted by certain pathogens and consider congenital disorders that affect phagocyte function. Copyright ©2012 by Annual Reviews. All rights reserved.
Hui C.-C.,Hospital for Sick Children |
Hui C.-C.,University of Toronto |
Angers S.,University of Toronto
Annual Review of Cell and Developmental Biology | Year: 2011
Gli zinc-finger proteins are transcription factors involved in the intracellular signal transduction controlled by the Hedgehog family of secreted molecules. They are frequently mutated in human congenital malformations, and their abnormal regulation leads to tumorigenesis. Genetic studies in several model systems indicate that their activity is tightly regulated by Hedgehog signaling through various posttranslational modifications, including phosphorylation, ubiquitin-mediated degradation, and proteolytic processing, as well as through nucleocytoplasmic shuttling. In vertebrate cells, primary cilia are required for the sensing of Hedgehog pathway activity and involved in the processing and activation of Gli proteins. Two evolutionarily conserved Hedgehog pathway components, Suppressor of fused and Kif7, are core intracellular regulators of mammalian Gli proteins. Recent studies revealed that Gli proteins are also regulated transcriptionally and posttranslationally through noncanonical mechanisms independent of Hedgehog signaling. In this review, we describe the regulation of Gli proteins during development and discuss possible mechanisms for their abnormal activation during tumorigenesis. © 2011 by Annual Reviews. All rights reserved.